Capricor Therapeutics initiated with a Buy at Roth Capital

Roth Capital initiated coverage of Capricor Therapeutics (CAPR) with a Buy rating and $31 price target The firm’s optimism on the shares is driven by “first-in-indication” deramiocel’s ability to improve cardiac and skeletal muscle function in Duchenne muscular dystrophy patients with cardiomyopathy. The firm expects a U.S. launch in Q4, with projected sales of $1B and $3.3B in 2030 and 2038, respectively.